Rationale and protocol design of a phase ii study of first-line osimertinib treatment for patients with poor performance status and egfr mutation-positive non-small cell lung cancer (open/torg2040)

HIGHLIGHTS

• who: Tomoya Fukui from the Department of Respiratory Medicine, Kitasato University School of Medicine, u201115u2011, Kitasato, Minamiu2011ku, Sagamihara, Kanagawa, u20110374, Japan have published the research work: Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040), in the Journal: (JOURNAL) of February/12,/2021
• what: Design Study design and treatment This study, whose objective is to assess the efficacy and safety of first-line osimertinib treatment in patients with advanced NSCLC harboring sensitive EGFR . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.